Journal: Journal of Translational Medicine
Article Title: Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment
doi: 10.1186/s12967-025-07450-x
Figure Lengend Snippet: Effects of Tr-ACT2 on a lung cancer cell model. ( A ) Effects of Tr-ACT2 on the growth of A549 cells at concentrations of 0.05 µM, 0.25 µM, and 1 µM for indicated time. Cell growth was evaluated using the MTT assay. ( B ) Representative images of A549 cell morphology at 48 h after treatment with 0.25 μM Tr-ACT2 or vehicle. Scale bar: 400 μm. ( C , D ) Western blot analysis showing the protein levels of PARP, cleaved PARP, IgG heavy chain, IgG light chain, and GAPDH in A549 cells treated with 0.25 μM Tr-ACT2 for indicated time. Protein levels are quantified by densitometry and normalized by GAPDH, versus 0 h. Data are presented as means ± SD ( n ≥ 4). p > 0.05 (ns), p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****)
Article Snippet: Human breast cancer cell lines SKBR3, JIMT1, BT549, MDA-MB-231, and the human non-small cell lung cancer (NSCLC) cell line A549 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic, at 37 °C and 5% CO2.
Techniques: MTT Assay, Western Blot